Non-surgical Treatment of Peri-implantitis With and Without Erythritol Air-polishing

Sponsor
Knut N. Leknes (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04152668
Collaborator
(none)
40
2
6.4

Study Details

Study Description

Brief Summary

Erythritol is a natural sugar alcohol (a four-carbon polyol) produced by the reduction of erythrose. It is considered safe as food additive and has many of the functional properties that are important for subgingival debridement. Current evidence includes no prospective studies comparing the outcomes of a low abrasive erythritol air-polishing as an adjunctive therapy to conventional titanium and ultrasonic debridement of patients in a maintenance program with peri-implantitis. Thus, the main purpose of this randomized, single-masked controlled trial (RCT) is to assess whether low abrasive erythritol air-polishing has an adjunct effect to conventional non-surgical treatment of peri-implantitis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Titanium curette.
  • Procedure: Ultrasonic
  • Procedure: Air-polishing
N/A

Detailed Description

This RCT will enroll subjects among patients in need for non-surgical treatment of peri-implantitis at a private dental clinic in Stavanger, Norway. Forty patients diagnosed with peri-implantitis on at least one implant will be randomly allocated by tossing a coin into test or control group. Patients with cement-retained and screw-retained supraconstructions will be included.

Treatment of peri-implantitis will be performed by one operator (AS) at baseline, 3-, 6-, 9- and 12-month follow-up visits. Local anesthesia will be used when needed. In the test group, implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit.

In the control group, implant with peri-implantitis will be debrided with titanium curette and ultrasonic device only. Test and control debridement will be performed without time limit. The treatment will continue until the operator is judging the implant surface to be free for supra- and subgingival deposits.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, single-masked controlled trial (RCT)Randomized, single-masked controlled trial (RCT)
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
Forty patients diagnosed with peri-implantitis on at least one implant will be randomly allocated by tossing a coin into test or control group. Two different operators will participate in the study (ML and AS). ML masked to the treatment assignment, will collect the data, and AS will perform the treatment.
Primary Purpose:
Treatment
Official Title:
Non-surgical Treatment of Peri-implantitis With and Without Erythritol Air-polishing: A 12-month Randomized Controlled Trial
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Feb 28, 2022
Anticipated Study Completion Date :
Jun 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Titanium curette and ultrasonic.

Control implants will be debrided with titanium curette and ultrasonic device without time limit.

Procedure: Titanium curette.
Implant debridement.

Procedure: Ultrasonic
Implant debridement.
Other Names:
  • Ultrasonic device
  • Experimental: Titanium curette, ultrasonic and air-polishing.

    Test implants will be treated with titanium curette, ultrasonic device and a specially designed nozzle mounted on a hand piece (Perio-Flow) connected to an airflow unit also without time limit.

    Procedure: Titanium curette.
    Implant debridement.

    Procedure: Ultrasonic
    Implant debridement.
    Other Names:
  • Ultrasonic device
  • Procedure: Air-polishing
    Implant debridement and polishing.
    Other Names:
  • Air-polishing device
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in probing depth (PD) [12 moths]

      PD as the distance in mm from the implant mucosal margin to the probable base of the pocket at six sites;

    2. Crestal bone level (CBL) [12 months]

      Intraoral digitalized radiographs will be taken with customized Eggen-holder and long cone, parallel technique to assess CBL. The distance from implant platform to the mesial and distal bone levels will be measured by using the software program DIGORA (Soredex, Helsinki).

    Secondary Outcome Measures

    1. Bleeding on probing (BoP) [12 months]

      BoP as the presence of bleeding after gentle probing (Renvert et al. 2017).

    2. Gingival crevicular fluid (GCF) [12 months]

      Sample sites will be isolated with cottons rolls, carefully cleaned for supragingival plaque and air-dried. A perio paper strip will then be gently placed one to two mm into the entrance of the pocket and left in place for 30 seconds.

    3. Visual analogue scale (VAS) [12 months]

      The scorings will be performed following completion of the debridement at baseline and at 6 and 12 months with 0 = "no pain" and 100 = "worst pain I can imagine".

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Healthy subjects aged 20 - 85 years who have received one or more dental implant(s) being in successful function for more than 12 months and restored with an optimal supraconstruction

    • Diagnosed with peri-implantitis based on the following criteria:

    • Bleeding and/or suppuration upon gentle probing

    • Increased probing depths (PD) compared with previous examinations or PD of ≥ 4 mm in at least one site around the implant

    • Crestal bone level (CBL) loss ≥2 mm compared with baseline registration

    Exclusion Criteria:
    • Surgical treatment of peri-implantitis the last 6 months

    • Supportive periodontal therapy within 3 months

    • Use of systemic antibiotic within 6 months

    • A history of non-compliant behavior

    • Inflammation around implant without evidence of bone loss

    • Periapical peri-implantitis

    • Subjects with implant fracture, ceramic implants, or detectable subgingival cement

    • Any current medical condition affecting the use of the abrasive air-polishing device.

    • Subjects with diabetes mellitus, cancer, HIV/aids, acute infections, liver or kidney dysfunction/failure,

    • Current pregnancy or breastfeeding

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Knut N. Leknes

    Investigators

    • Principal Investigator: Knut N. Leknes, Professor, Department of Clinical Dentistry - Periodontics, University of Bergen, NORWAY

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Knut N. Leknes, Professor, University of Bergen
    ClinicalTrials.gov Identifier:
    NCT04152668
    Other Study ID Numbers:
    • UiB, IKO 2019
    First Posted:
    Nov 5, 2019
    Last Update Posted:
    Oct 5, 2021
    Last Verified:
    Oct 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Knut N. Leknes, Professor, University of Bergen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 5, 2021